Skip to main content

Advertisement

SpringerLink
Log in

Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literature

  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Our aim was to review our experience of trientine as chelation therapy in children with Wilson disease (WD) and compare to that reported in the literature. We made a retrospective review of the medical notes of 16 of 96 (17%) children diagnosed with WD between 1981 and 2006. Children were 6.6 to 15 years old. Only three received trientine as initial therapy [parental choice (two), allergic reactions to penicillamine (one) during the penicillamine challenge], 13 of 16 were converted from penicillamine to trientine because of reactions to penicillamine: haematuria in four, bone marrow suppression in three, neutropenia in three. Trientine was discontinued in three due to allergic rash, low copper excretion and one with compliance problems requiring transplantation. Seventy-five per cent of children presented with chronic liver disease. Kayser–Fleischer rings were noticed in eight of 16, Wilson Ferenci score range was between 4 and 10 (nl < 4). Laboratory indices remained relatively stable. In line with previous reports, trientine was used mainly as secondary treatment when there were severe side effects with penicillamine. Whilst the current evidence is low quality, it appears that trientine is as efficacious as penicillamine and small population studies show a lower side effect profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AST:

Aspartate aminotransferase

INR:

International normalised ratio

MRI:

Magnetic resonance imaging

References

  1. Ala A, Walker AP, Ashkan K et al (2007) Wilson’s disease. Lancet 369:397–408 doi:10.1016/S0140-6736(07)60196-2

    Article  PubMed  CAS  Google Scholar 

  2. Arnon R, Flores Calderon J, Schilsky M et al (2007) Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. JPGN 44:596–602

    PubMed  CAS  Google Scholar 

  3. Askari FK, Greenson J, Dick RB et al (2003) Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 142:385–390 doi:10.1016/S0022-2143(03)00157-4

    Article  PubMed  CAS  Google Scholar 

  4. Brewer GJ (2005) Neurologically presenting Wilson’s disease. Epidemiology, pathophysiology and treatment. CNS Drugs 19:185–192 doi:10.2165/00023210-200519030-00001

    Article  PubMed  CAS  Google Scholar 

  5. Brewer GJ, Askari F, Lorincz MT et al (2006) Treatment of Wilson disease with ammonium tetrathiomolybdate. IV Comparison of tetrathiomolybdate and trientine in a double blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:521–527 doi:10.1001/archneur.63.4.521

    Article  PubMed  Google Scholar 

  6. Brewer GJ, Dick RB, Johnson JA et al (1999) The treatment of Wilson’s disease with zinc. J Lab Clin Med 134:322–324 doi:10.1016/S0022-2143(99)90213-5

    Article  PubMed  CAS  Google Scholar 

  7. Brewer GJ, Johnson V, Dick RD et al (1996) Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017–1025

    PubMed  CAS  Google Scholar 

  8. Czlonkowska A, Gajda J, Rodo M (1996) Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol 243:269–273 doi:10.1007/BF00868525

    Article  PubMed  CAS  Google Scholar 

  9. Dahlman T, Hartvig P, Lofholm M et al (1995) Long-term treatment of Wilson’s disease with triethylene tetramine dihydrochloride (trientine). Q J Med 88:609–616

    CAS  Google Scholar 

  10. Dhawan A, Taylor RM, Cheeseman P et al (2005) Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transplant 11:441–448 doi:10.1002/lt.20352

    Article  Google Scholar 

  11. Dubois RS, Rodgerson DO, Hambridge KM (1990) Treatment of Wilson’s disease with triethylene tetramine hydrochloride (trientine). JPGN 10:77–81

    PubMed  CAS  Google Scholar 

  12. Ferenci P (2004) Review article: diagnosis and current therapy of Wilson’s disease. Aliment Pharmacol Ther 19:157–165 doi:10.1046/j.1365-2036.2003.01813.x

    Article  PubMed  CAS  Google Scholar 

  13. Kumagi T, Horiike N, Michitaka K et al (2004) Recent clinical features of Wilson’s disease with hepatic presentation. J Gastroenterol 39:1165–1169 doi:10.1007/s00535-004-1466-y

    Article  PubMed  Google Scholar 

  14. Mann T (1996) Clinical guidelines: using clinical guidelines to improve patient care within the NHS. NHS Executive, Leeds, UK

    Google Scholar 

  15. Merle U, Schaefer M, Ferenci P et al (2007) Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 56:115–120 doi:10.1136/gut.2005.087262

    Article  PubMed  CAS  Google Scholar 

  16. Meyers KEC, Thomson PD, Weiland H (1996) Noncompliance in children and adolescents after renal transplantation. Transplant 62:186–189 doi:10.1097/00007890-199607270-00007

    Article  CAS  Google Scholar 

  17. Moons P, De Geest S, Abraham I et al (1998) Symptom experience associated with maintenance immunosuppression after heart transplantation: patient’s appraisal of side effects. Heart Lung 27:315–325 doi:10.1016/S0147-9563(98)90052-8

    Article  PubMed  CAS  Google Scholar 

  18. Morita J, Yoshino M, Watari H et al (1992) Wilson’s disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCL): long-term observations. Dev Pharmacol Ther 19:6–9

    PubMed  CAS  Google Scholar 

  19. Saito H, Watanabe K, Sahara M et al (1991) Triethylene-tetramine (trien) therapy for Wilson’s disease. Tohoku J Exp Med 164:29–35 doi:10.1620/tjem.164.29

    Article  PubMed  CAS  Google Scholar 

  20. Scheinberg IH, Jaffe ME, Sternlieb I (1987) The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. N Engl J Med 317:209–213

    PubMed  CAS  Google Scholar 

  21. Siegemund R, Lossner J, Gunther K et al (1991) Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson’s disease. Acta Neurol Scand 83:364–366

    Article  PubMed  CAS  Google Scholar 

  22. Walshe JM (1956) Penicillamine, a new oral therapy for Wilson’s disease. Am J Med 21:487–495 doi:10.1016/0002-9343(56)90066-3

    Article  PubMed  CAS  Google Scholar 

  23. Walshe JM (1973) Copper chelation in patients with Wilson’s disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 167:441–452

    Google Scholar 

  24. Walshe JM (1982) Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643–647 doi:10.1016/S0140-6736(82)92201-2

    Article  PubMed  CAS  Google Scholar 

  25. Walshe JM (1986) The management of pregnancy in Wilson’s disease treated with trientine. Q J Med 58:81–87

    PubMed  CAS  Google Scholar 

  26. Walshe JM (1969) The management of pencillamine nephropathy in Wilson’s disease. Lancet 2:1401–1402 doi:10.1016/S0140-6736(69)90940-4

    Article  PubMed  CAS  Google Scholar 

  27. Walshe JM (1986) Dangers of non-compliance in Wilson’s disease. Lancet 1:845–847 doi:10.1016/S0140-6736(86)90949-9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Liver Centre, King’s College London School of Medicine at King’s College Hospital NHS Foundation Trust, London, UK

    Rachel M. Taylor, Yuan Chen & Anil Dhawan

  2. Florence Nightingale School of Nursing & Midwifery, King’s College London, London, UK

    Rachel M. Taylor

  3. Department of Pediatrics, The 2nd Hospital of Hebei Medical University, Shijiazhuang, China

    Yuan Chen

  4. Paediatric Liver Centre, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK

    Anil Dhawan

Authors
  1. Rachel M. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil Dhawan
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EuroWilson Consortium

Corresponding author

Correspondence to Anil Dhawan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, R.M., Chen, Y., Dhawan, A. et al. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literature. Eur J Pediatr 168, 1061–1068 (2009). https://doi.org/10.1007/s00431-008-0886-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-008-0886-8

Keywords

Search

Navigation